title: Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
abstract: Sclerodermatous chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) in children is difficult to treat and life-threatening. Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy that involves the infusion of autologous peripheral blood leukocytes after ex vivo exposure to the photoactive agent 8-methoxypsoralen and ultraviolet A radiation, is an effective treatment for steroid-refractory cGVHD. After undergoing allogeneic HSCT for pre-B-cell acute lymphoblastic leukemia, a 14-year-old boy developed extensive sclerodermatous cGVHD that was refractory to prednisone, tacrolimus, and sirolimus. ECP was administered over the course of 53 months, during which the skin softened substantially and immunosuppressive therapy was discontinued. This case suggests that long-term ECP is a viable option in children with sclerodermatous cGVHD.
authors: Columbia University College of Physicians and Surgeons, New York, NY, USA. emil.bisaccia@atlantichealth.org
authors: Emil
authors: E
authors: Bisaccia
authors: Mark
authors: M
authors: Palangio
authors: Joselyn
authors: J
authors: Gonzalez
mesh_terms: D000293:Adolescent; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D017893:Photopheresis / Q000379:methods*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D011241:Prednisone